Skip to content
DataLookout
Menu

NCT07332429

Efficacy and Safety of Alcovit in Reducing Blood Alcohol Concentration

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from May 30, 2026 to Jan 20, 2027 Show 4 more changesShow less
    • Start date: May 30, 2026 to Jan 20, 2027
    • Eligibility criteria expanded, about 13 words
    • Study completion pushed from May 30, 2027 to Jun 30, 2027
    • Secondary endpoints: details revised at 1 of 10 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Reduction in Blood Alcohol Levels and Breathalyzer Readings - Pre-consumption Administration
Timeframe: Baseline (30 minutes before), 20 minutes, 40 minutes, and 60 minutes after alcohol consumption (Day 1)
Reduction in Blood Alcohol Levels and Breathalyzer Readings - Post-consumption Administration
Timeframe: Baseline (30 minutes before), 20 minutes, 40 minutes, and 60 minutes after alcohol consumption (Day 1).

Secondary (10)

Correlation Between Blood Alcohol Reduction and Breathalyzer Readings
Correlation Between Elimination Rate in Blood and Breathalyzer
Hangover Symptom Severity Using AHSS
Participant Experience with Alcovit® (Patient-Reported Outcomes)
Adverse Events Reported by Participants (Clinician-Reported Outcomes)
Show 5 moreShow less
Number and Type of Adverse Events (Clinician-Reported Outcomes)
Changes in Hepatic Function Markers (Clinician-Reported Outcomes)
Changes in Renal Function Markers (Clinician-Reported Outcomes)
Ease of Handling and Administration (Clinician-Reported Outcomes/Patient-Reported Outcomes)
Baseline Population Characteristics (Clinician-Reported Outcomes)

Arms and interventions

Alcovit (Pre-consumption)Experimental

Participants receive the investigational device immediately before (2-3 minutes) consuming the standardized alcohol dose.

Alcovit (Post-consumption)Experimental

Participants receive the investigational device immediately after (maximum 5 minutes) consuming the standardized alcohol dose.

Placebo (Pre-consumption)Placebo comparator

Participants receive the placebo immediately before consuming the standardized alcohol dose.

Placebo (Post-consumption)Placebo comparator

Participants receive the placebo immediately after consuming the standardized alcohol dose.

Devices: Alcovit® (Zeolite Clinoptilolite), Placebo

Sites

1 site in 1 country

  • Hospital Santa Casa de Misericórdia de CamposCampos dos Goytacazes, Rio de Janeiro, Brazil